Authors : Gayathri.Vana; Dr. Nimmala Phani Satyavathi; Vaddadi.Poojitha; Imaraka.Charishma

Volume/Issue : Volume 10 - 2025, Issue 3 - March

Google Scholar : https://tinyurl.com/vp2k66k4

Scribd : https://tinyurl.com/3c7yx8fk

DOI : https://doi.org/10.38124/ijisrt/25mar486

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : Hypertension remains a global health challenge, contributing significantly to cardiovascular morbidity and mortality. Despite the availability of various antihypertensive drugs, many patients fail to achieve optimal blood pressure control due to factors such as medication resistance, side effects, and patient non-adherence [1]. Recent research has led to groundbreaking advancements in hypertension treatment, including novel pharmacological therapies, gene-targeted interventions, and innovative non-pharmacological approaches. New classes of drugs, such as angiotensin receptor neprilysin inhibitors (ARNIs) and endothelin receptor antagonists, have demonstrated superior efficacy in blood pressure reduction compared to traditional therapies [2]. Additionally, gene-editing technologies like CRISPR-Cas9 are being explored for their potential to modulate genes associated with hypertension [3]. Non-pharmacological innovations, such as renal denervation therapy and bioelectronic medicine, offer alternative strategies for treatment-resistant hypertension [4]. Moreover, artificial intelligence (AI) and machine learning are transforming hypertension management by enabling personalized treatment plans based on predictive analytics [5]. This article reviews these emerging therapies, their clinical implications, and the barriers that need to be overcome for widespread adoption. The integration of these new treatment modalities has the potential to revolutionize hypertension management and improve patient outcomes worldwide.

Keywords : Hypertension, Antihypertensive Therapy, Renal Denervation, Gene Therapy, Artificial Intelligence, CRISPR-Cas9, Personalized Medicine, Cardiovascular Disease, Pharmacogenomics, Endothelin Receptor Antagonists

References :

1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for hypertension management. J Am Coll Cardiol. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006
2. Mills KT, Bundy JD, Kelly TN, et al. Global epidemiology of hypertension. J Am Coll Cardiol. 2016;67(11):1231-1241. doi:10.1016/j.jacc.2015.12.006
3. Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124-1140. doi:10.1161/CIRCRESAHA.118.313220
4. Oparil S, Acelajado MC, Bakris GL, et al. Hypertension. Nat Rev Dis Primers. 2018;4(1):18014. doi:10.1038/nrdp.2018.14
5. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines on hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339
6. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control. Lancet. 2021;398(10304):957-980. doi:10.1016/S0140-6736(21)01330-1
7. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol. 2020;76(25):2982-3021. doi:10.1016/j.jacc.2020.11.010
8. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802. doi:10.1038/s41569-021-00559-8
9. Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976-990. doi:10.1161/CIRCRESAHA.116.303604
10. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568):1208-1219. doi:10.1016/S0140-6736(07)60242-6
11. Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction and vascular disease in later life. Maturitas. 2010;67(1):20-24. doi:10.1016/j.maturitas.2010.04.011
12. Harrison DG, Coffman TM, Wilcox CS. Pathophysiology of hypertension: The mosaic theory and beyond. Circ Res. 2021;128(7):847-863. doi:10.1161/CIRCRESAHA.121.318082
13. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339
14. Vrijens B, Antoniou S, Burnier M, et al. Current situation of medication adherence and persistence in hypertension. J Hypertens. 2017;35(7):1481-1491. doi:10.1097/HJH.0000000000001284
15. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: Detection, evaluation, and management. Hypertension. 2018;72(5):e53-e90. doi:10.1161/HYP.0000000000000084
16. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237. doi:10.1038/s41581-019-0244-2
17. Kario K. Emerging hypertension complexity and the new strategy for risk cardiovascular management. Circ J. 2021;85(9):1612-1621. doi:10.1253/circj.CJ-21-0388
18. Verdecchia P, Angeli F, Reboldi G. Beyond RAAS inhibition: An update on novel antihypertensive agents. Hypertension. 2020;76(3):884-893. doi:10.1161/HYPERTENSIONAHA.120.14735
19. Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res. 2015;116(6):937-959. doi:10.1161/CIRCRESAHA.116.303647
20. Omboni S, McManus RJ, Bosworth HB, et al. Evidence and recommendations on the use of telemedicine for the management of arterial hypertension. Hypertension. 2020;76(5):1368-1383. doi:10.1161/HYPERTENSIONAHA.120.15873
21. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension. Hypertension. 2006;47(2):296-308. doi:10.1161/01.HYP.0000202568.01167.B6
22. Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116(6):1074-1095. doi:10.1161/CIRCRESAHA.116.303603
23. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339
24. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077
25. Agarwal R, Rossignol P, Romero A, et al. Effect of baxdrostat on blood pressure in treatment-resistant hypertension. Lancet. 2023;401(10382):419-431. doi:10.1016/S0140-6736(22)02119-6
26. Dhaun N, Goddard J, Kohan DE, et al. Role of endothelin-1 in hypertension. Hypertension. 2008;52(4):452-459. doi:10.1161/HYPERTENSIONAHA.108.117366
27. Burnier M, Polychronopoulou E, Wuerzner G. Clinical benefits of fixed-dose combination therapies in hypertension management: An update. Eur Heart J. 2020;41(27):3000-3013. doi:10.1093/eurheartj/ehz861
28. Chow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959-968. doi:10.1001/jama.2013.184182
29. Gradman AH, Basile JN, Carter BL, et al. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011;13(3):146-154. doi:10.1111/j.1751-7176.2010.00410.x
30. Turner ST, Schwartz GL, Chapman AB, et al. Pharmacogenomics of essential hypertension. Clin Pharmacol Ther. 2006;79(1):197-210. doi:10.1016/j.clpt.2005.11.006
31. Ji W, Foo JN, O’Roak BJ, et al. Genetic analysis of blood pressure reveals novel associated loci. Hum Mol Genet. 2013;22(5):1096-1103. doi:10.1093/hmg/dds548
32. Fuster V, Narula J. Emerging peptide therapies for hypertension. J Am Coll Cardiol. 2015;66(15):1692-1695. doi:10.1016/j.jacc.2015.08.020
33. Hopkins CR, Groom CR. RNA-based therapeutics for hypertension. Nat Rev Drug Discov. 2022;21(6):413-431. doi:10.1038/s41573-021-00284-6
34. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for hypertension. J Am Coll Cardiol. 2014;63(12):1235-1238. doi:10.1016/j.jacc.2013.11.005
35. Joseph JJ, Echouffo-Tcheugui JB, Golden SH. New insights into the epidemiology of hypertension-mediated end-organ damage. Curr Hypertens Rep. 2017;19(8):76. doi:10.1007/s11906-017-0760-3
36. Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin receptor blockers and risk of cancer. Lancet Oncol. 2018;19(3):e127-e136. doi:10.1016/S1470-2045(18)30098-7
37. Carretero OA, Oparil S. Essential hypertension: part I: definition and etiology. Circulation. 2000;101(3):329-335. doi:10.1161/01.CIR.101.3.329
38.   Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245-1254. doi:10.1093/eurheartj/eht534
39.   Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for hypertension management. J Am Coll Cardiol. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006
40. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077
41. Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly. Hypertension. 2017;69(3):411-420. doi:10.1161/HYPERTENSIONAHA.116.08424
42. Patel P, Cattran D. The role of aldosterone synthase inhibitors in managing hypertension. J Clin Hypertens. 2020;22(1):10-15. doi:10.1111/jch.13811
43. Rocha R, Funder JW. The role of aldosterone in cardiovascular disease. J Clin Endocrinol Metab. 2002;87(11):4754-4756. doi:10.1210/jc.2002-021078
44. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016;68(2):357-418. doi:10.1124/pr.115.011833
45. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37(1):67-119. doi:10.1093/eurheartj/ehv317
46. Azizi M, Amar L, Gosse P, et al. Endothelin receptor antagonists for hypertension treatment: Current status and future perspectives. Curr Hypertens Rep. 2021;23(7):24. doi:10.1007/s11906-021-01133-2
47. Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116(6):1074-1095. doi:10.1161/CIRCRESAHA.116.303603
48.   Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the DASH diet. N Engl J Med. 2001;344(1):3-10. doi:10.1056/NEJM200101043440101
49. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension. Hypertension. 2006;47(2):296-308. doi:10.1161/01.HYP.0000202568.01167.B6
50. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for hypertension management. J Am Coll Cardiol. 2018;71(19):e127-e248. doi:10.1016/j.jacc.2017.11.006
51. He FJ, MacGregor GA. A comprehensive review on salt and health. J Hum Hypertens. 2009;23(7):363-384. doi:10.1038/jhh.2008.144
52. Piercy KL, Troiano RP, Ballard RM, et al. The physical activity guidelines for Americans. JAMA. 2018;320(19):2020-2028. doi:10.1001/jama.2018.14854
53. Cornelissen VA, Smart NA. Exercise training for blood pressure: A systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473. doi:10.1161/JAHA.112.004473
54. Neter JE, Stam BE, Kok FJ, et al. Influence of weight reduction on blood pressure: A meta-analysis of randomized controlled trials. Hypertension. 2003;42(5):878-884. doi:10.1161/01.HYP.0000094221.86888.AE
55. Beilin LJ, Puddey IB. Alcohol and hypertension: An update. Hypertension. 2006;47(6):1035-1038. doi:10.1161/01.HYP.0000226111.17020.7a
56. Virdis A, Giannarelli C, Neves MF, et al. Cigarette smoking and hypertension. Curr Pharm Des. 2010;16(23):2518-2525. doi:10.2174/138161210792062920
57. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: A meta-analysis of randomized controlled trials. CMAJ. 2008;179(2):135-144. doi:10.1503/cmaj.070256
58. Palta P, Page G, Piferi RL, et al. Evaluation of a mindfulness-based intervention program to decrease blood pressure in low-income African-American older adults. J Urban Health. 2012;89(2):308-316. doi:10.1007/s11524-011-9644-z
59. Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: The PREMIER clinical trial. JAMA. 2006;298(19):2083-2093. doi:10.1001/jama.298.19.2083
60. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med. 2001;344(1):3-10. doi:10.1056/NEJM200101043440101
61. Appel LJ, Brands MW, Daniels SR, et al. Dietary approaches to prevent and treat hypertension. Hypertension. 2006;47(2):296-308. doi:10.1161/01.HYP.0000202568.01167.B6
62. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2(1):e004473. doi:10.1161/JAHA.112.004473
63. Pescatello LS, MacDonald HV, Lamberti L, et al. Exercise for hypertension: A prescription update integrating existing recommendations with emerging research. Curr Hypertens Rep. 2015;17(11):87. doi:10.1007/s11906-015-0600-y
64. Blumenthal JA, Sherwood A, Smith PJ, et al. Enhancing cardiac rehabilitation with stress management training. Circ. 2016;133(14):1341-1350. doi:10.1161/CIRCULATIONAHA.115.018926
65. Park SH, Han KS. Blood pressure response to meditation and yoga: A systematic review and meta-analysis. J Altern Complement Med. 2017;23(9):685-695. doi:10.1089/acm.2017.0087
66. Flachskampf FA, Gallasch J, Gefeller O, et al. Randomized trial of acupuncture to lower blood pressure. Circulation. 2007;115(24):3121-3129. doi:10.1161/CIRCULATIONAHA.106.683201
67. Faulkner MS. Cardiovascular fitness and quality of life in adolescents with type 1 or type 2 diabetes. J Spec Pediatr Nurs. 2010;15(4):307-316. doi:10.1111/j.1744-6155.2010.00251.x
68. Dickinson HO, Mason JM, Nicolson DJ, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. J Hypertens. 2006;24(2):215-233. doi:10.1097/01.hjh.0000199800.72563.26
69. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153. doi:10.1056/NEJM200001203420301
70. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995-1003. doi:10.1016/S0140-6736(02)08089-3
71. Staessen JA, Li Y, Richart T. Oral antihypertensive treatment and blood pressure reduction: clinical implications. J Hypertens. 2006;24(2):235-242. doi:10.1097/01.hjh.0000199802.11176.7f
72. Brown MJ, Cruickshank JK, Dominiczak AF, et al. Better blood pressure control: combining calcium channel blockers with other agents. J Hum Hypertens. 2003;17(1):81-85. doi:10.1038/sj.jhh.1001507
73. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009;(3):CD001841. doi:10.1002/14651858.CD001841.pub2
74. Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomized, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. doi:10.1016/S0140-6736(15)00257-3
75. Bangalore S, Messerli FH, Wun CC, et al. Cardiovascular protection using beta-blockers: A critical review of the evidence. J Am Coll Cardiol. 2007;50(7):563-572. doi:10.1016/j.jacc.2007.04.073
76. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061
77. Calhoun DA, White WB. Effectiveness of aldosterone antagonists in resistant hypertension. Hypertension. 2008;51(3):747-752. doi:10.1161/HYPERTENSIONAHA.107.105122
78. Iglarz M, Clozel M. Endothelin receptor antagonists: past, present, and future. Curr Opin Pharmacol. 2010;10(2):176-181. doi:10.1016/j.coph.2009.12.003
79. Ruilope LM, Agarwal R. Neprilysin inhibition and angiotensin receptor blockade in heart failure and hypertension. J Hypertens. 2018;36(7):1513-1523. doi:10.1097/HJH.0000000000001761
80. Turner ST, Bailey KR, Schwartz GL, et al. Genomic predictors of antihypertensive response to metoprolol and hydrochlorothiazide. Hypertension. 2012;59(5):1133-1140. doi:10.1161/HYPERTENSIONAHA.111.190850
81. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Pharmacol Rev. 2013;65(3):987-1009. doi:10.1124/pr.112.007252
82. Pereira TV, Polonia J, Monteiro EC. Pharmacogenetics of antihypertensive therapy. Pharmacogenomics J. 2011;11(1):1-11. doi:10.1038/tpj.2010.15
83. Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nat Rev Cardiol. 2019;16(8):491-502. doi:10.1038/s41569-019-0187-7
84. Ruilope LM, Tamargo J. Aldosterone synthase inhibitors in hypertension. J Clin Hypertens. 2018;20(1):4-10. doi:10.1111/jch.13161
85. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med. 2017;14(9):e1002389. doi:10.1371/journal.pmed.1002389
86. Green BB, Anderson ML, Ralston JD, et al. Patient-centered web services for hypertension management: a randomized controlled trial. JAMA Intern Med. 2013;173(10):957-965. doi:10.1001/jamainternmed.2013.2751
87. Marques FZ, Mackay CR, Kaye DM. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018;15(1):20-32. doi:10.1038/nrcardio.2017.120
88. Khalesi S, Sun J, Buys N, et al. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension. 2014;64(4):897-903. doi:10.1161/HYPERTENSIONAHA.114.03469
89. Omboni S. Telemedicine during the COVID-19 in Italy: a missed opportunity? Telemed J E Health. 2020;26(9):973-975. doi:10.1089/tmj.2020.0106
90. Bove AA. Telemedicine and hypertension management. J Clin Hypertens. 2020;22(9):1470-1474. doi:10.1111/jch.13988
91. Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116(6):1074-1095. doi:10.1161/CIRCRESAHA.116.303603
92. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Pharmacol Rev. 2013;65(3):987-1009. doi:10.1124/pr.112.007252
93. Ruilope LM, Tamargo J. Aldosterone synthase inhibitors in hypertension. J Clin Hypertens. 2018;20(1):4-10. doi:10.1111/jch.13161
94. Tucker KL, Sheppard JP, Stevens R, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med. 2017;14(9):e1002389. doi:10.1371/journal.pmed.1002389
95. Marques FZ, Mackay CR, Kaye DM. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018;15(1):20-32. doi:10.1038/nrcardio.2017.120
96. Omboni S. Telemedicine during the COVID-19 in Italy: a missed opportunity? Telemed J E Health. 2020;26(9):973-975. doi:10.1089/tmj.2020.0106
97. Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res. 2015;116(6):1074-1095. doi:10.1161/CIRCRESAHA.116.303603